Advaxis (NASDAQ:ADXS) received a $19.00 price target from research analysts at Cantor Fitzgerald in a report released on Friday. The brokerage currently has a “buy” rating on the biotechnology company’s stock.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.